Scientific Director Biogen Cambridge, Massachusetts, United States
Multiple efforts to develop and validate fluid-based biomarkers for neurologic conditions are ongoing by academic and pharmaceutical institutions. These biomarkers can be used to detect and predict alterations in the nervous system in nonclinical studies and humans and to evaluate efficacy of new drugs and monitor neurologic disease progression. During this presentation, the use of different fluid-based biomarkers will be discussed, and the role of different scientists play in validation and interpreting biomarker data in preclinical studies.
